These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 10097686)
41. In vitro activity of tigecycline against Bacteroides species. Betriu C; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ J Antimicrob Chemother; 2005 Aug; 56(2):349-52. PubMed ID: 15951353 [TBL] [Abstract][Full Text] [Related]
42. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390 [TBL] [Abstract][Full Text] [Related]
43. Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group. Cuchural GJ; Tally FP; Jacobus NV; Cleary T; Finegold SM; Hill G; Iannini P; O'Keefe JP; Pierson C Antimicrob Agents Chemother; 1990 Mar; 34(3):479-80. PubMed ID: 2334161 [TBL] [Abstract][Full Text] [Related]
44. Mechanisms of resistance in anaerobes and new developments in testing. Finegold SM Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):117S-120S. PubMed ID: 2686914 [TBL] [Abstract][Full Text] [Related]
45. Clinico-microbiological profile of Gupta A; Shenoy PA; Kumar A; Chawla K Indian J Med Res; 2021 May; 154(5):750-756. PubMed ID: 35532593 [TBL] [Abstract][Full Text] [Related]
46. [Antibiotic sensitivity of Bacteroides fragilis group in Algeria]. Merad AS; Ghemati M; Faid N; Kimouche N Arch Inst Pasteur Alger; 1998; 62():91-110. PubMed ID: 11256322 [TBL] [Abstract][Full Text] [Related]
47. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Cuchural GJ; Tally FP; Jacobus NV; Aldridge K; Cleary T; Finegold SM; Hill G; Iannini P; O'Keefe JP; Pierson C Antimicrob Agents Chemother; 1988 May; 32(5):717-22. PubMed ID: 3395102 [TBL] [Abstract][Full Text] [Related]
49. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Labbé AC; Bourgault AM; Vincelette J; Turgeon PL; Lamothe F Antimicrob Agents Chemother; 1999 Oct; 43(10):2517-9. PubMed ID: 10508035 [TBL] [Abstract][Full Text] [Related]
50. Bacteroides, Prevotella, and Porphyromonas species: a review of antibiotic resistance and therapeutic options. Falagas ME; Siakavellas E Int J Antimicrob Agents; 2000 Jun; 15(1):1-9. PubMed ID: 10856670 [TBL] [Abstract][Full Text] [Related]
51. Bacteroides fragilis: current susceptibilities, mechanisms of drug resistance, and principles of antimicrobial therapy. Cuchural GJ; Tally FP Drug Intell Clin Pharm; 1986; 20(7-8):567-73. PubMed ID: 3488895 [TBL] [Abstract][Full Text] [Related]
52. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea. Lee Y; Park Y; Kim MS; Yong D; Jeong SH; Lee K; Chong Y Antimicrob Agents Chemother; 2010 Sep; 54(9):3993-7. PubMed ID: 20585132 [TBL] [Abstract][Full Text] [Related]